Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Hill

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
BMJ Open|January 20, 2025
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trialMelanie Varley, Joanne Euden, Richard Adams, et al.
Nature Communications|July 31, 2021
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trialPedro M Folegatti, Kate Harrison, Lorena Preciado-Llanes, et al.
Science Translational Medicine|November 8, 2014
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memoryLeo Swadling, Stefania Capone, Richard D Antrobus, et al.
Science Translational Medicine|January 6, 2012
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in manEleanor Barnes, Antonella Folgori, Stefania Capone, et al.
Research Square|June 12, 2025
Identification of cross-stage, cross-species malaria CD8+ T cell antigensCaroline Junqueira, Camila R R Barbosa Barbosa, Luna de Lacerda, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
Wellcome Open Research|May 6, 2024
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trialMainga Hamaluba, Samuel Sang, Benedict Orindi, et al.
Tuberculosis (Edinburgh, Scotland)|February 3, 2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosisAnn Williams, Graham J Hatch, Simon O Clark, et al.
Plos One|September 8, 2021
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adultsMarvin J Sklar, Santina Maiolatesi, Noelle Patterson, et al.
Nature Genetics|May 19, 2015
Factors influencing success of clinical genome sequencing across a broad spectrum of disordersJenny C Taylor, Hilary C Martin, Stefano Lise, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
BMJ Open|January 20, 2025
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trialMelanie Varley, Joanne Euden, Richard Adams, et al.
Nature Communications|July 31, 2021
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trialPedro M Folegatti, Kate Harrison, Lorena Preciado-Llanes, et al.
Science Translational Medicine|November 8, 2014
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memoryLeo Swadling, Stefania Capone, Richard D Antrobus, et al.
Science Translational Medicine|January 6, 2012
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in manEleanor Barnes, Antonella Folgori, Stefania Capone, et al.
Research Square|June 12, 2025
Identification of cross-stage, cross-species malaria CD8+ T cell antigensCaroline Junqueira, Camila R R Barbosa Barbosa, Luna de Lacerda, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
Wellcome Open Research|May 6, 2024
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trialMainga Hamaluba, Samuel Sang, Benedict Orindi, et al.
Tuberculosis (Edinburgh, Scotland)|February 3, 2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosisAnn Williams, Graham J Hatch, Simon O Clark, et al.
Plos One|September 8, 2021
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adultsMarvin J Sklar, Santina Maiolatesi, Noelle Patterson, et al.
Nature Genetics|May 19, 2015
Factors influencing success of clinical genome sequencing across a broad spectrum of disordersJenny C Taylor, Hilary C Martin, Stefano Lise, et al.
Pageof 3